How Valeant Tripled Prices, Doubled Sales of Flatlining Drug

  • Wellbutrin antidepressant gets new life with free co-pays
  • List price increased 11 times since 2014 to $17,000 a year

Why Schiller as Interim CEO Is Good for Valeant

No wonder investors once loved Michael Pearson. In short order, he managed to double sales of Wellbutrin XL, the popular antidepressant, even though far cheaper generics were out there.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.